Key Points
- Carlsmed COO Jeffrey Bertolini sold 747 shares at an average price of $14.39, generating $10,749.33 and reducing his direct ownership by 3.21% to 22,489 shares. He also sold 243 shares in a prior transaction.
- Carlsmed shares opened at $14.64 after declining 4.3%; the company has a market capitalization of approximately $399.7 million and reported quarterly revenue of $18.94 million with a loss of $0.39 per share.
- Analysts maintain a generally positive view, with four Buy ratings, one Hold, and one Sell; the stock has a Moderate Buy consensus rating and an average price target of $19.25.
Carlsmed, Inc. (NASDAQ:CARL - Get Free Report) COO Jeffrey Bertolini sold 747 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $14.39, for a total value of $10,749.33. Following the transaction, the chief operating officer directly owned 22,489 shares of the company's stock, valued at approximately $323,616.71. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Jeffrey Bertolini also recently made the following trade(s):
- On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $13.99, for a total value of $3,399.57.
Carlsmed Stock Down 4.3%
Shares of CARL opened at $14.64 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The stock has a market capitalization of $399.72 million, a price-to-earnings ratio of -10.24 and a beta of 2.09. Carlsmed, Inc. has a 1 year low of $8.50 and a 1 year high of $17.23. The business's 50 day simple moving average is $14.83 and its 200-day simple moving average is $12.17.
Carlsmed (NASDAQ:CARL - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The firm had revenue of $18.94 million during the quarter. As a group, equities analysts expect that Carlsmed, Inc. will post -1.5 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Carlsmed
Large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Carlsmed in the second quarter worth $5,528,000. Janus Henderson Group PLC boosted its stake in shares of Carlsmed by 7.6% during the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company's stock valued at $11,108,000 after purchasing an additional 86,834 shares during the period. KCM Capital Inc bought a new position in shares of Carlsmed in the first quarter worth about $1,810,000. Parkman Healthcare Partners LLC bought a new position in shares of Carlsmed in the second quarter worth about $6,200,000. Finally, Jupiter Topco LLC purchased a new position in Carlsmed in the 2nd quarter worth about $12,992,000.
Analyst Ratings Changes
Several analysts have recently issued reports on CARL shares. Wall Street Zen upgraded shares of Carlsmed from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Weiss Ratings upgraded Carlsmed from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Truist Financial upped their price objective on Carlsmed from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Needham & Company LLC started coverage on Carlsmed in a report on Wednesday, July 1st. They issued a "buy" rating and a $17.00 target price for the company. Finally, BTIG Research reissued a "buy" rating and set a $23.00 target price on shares of Carlsmed in a research report on Monday, September 28th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Carlsmed presently has an average rating of "Moderate Buy" and an average price target of $19.25.
View Our Latest Report on CARL
Carlsmed Company Profile
(
Get Free Report)
Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient's anatomy and surgical goals.
Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
